Home > Healthcare > Pharmaceuticals > Clinical Nutrition > Intravenous Solutions Market

Intravenous Solutions Market Trends

Report ID: GMI8359
Published Date: Mar 2024
Report Format: PDF

Download Free Sample

Intravenous Solutions Market Trends

The high prevalence of preterm births, particularly in emerging economies such as China, India is projected to drive the market growth.
According to the data published by Healthy Newborn Network Organization every year around 3,341,000 babies are born preterm in India. Therefore, high incidence of preterm births in developing economies, coupled with other factors such as growing healthcare expenditure, improved healthcare infrastructure, and patient awareness will stimulate market growth.
Additionally, high prevalence of preterm births has spurred research and development efforts to improve IV therapy delivery systems and formulations specifically designed for neonatal patients. This includes innovations in IV catheters, infusion pumps, and IV solution compositions optimized for neonatal care.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Intravenous solutions industry size was USD 13 billion in 2023 and is expected to reach USD 24.8 billion by 2032, driven by the growing geriatric population, increasing cases of malnutrition, and high prevalence of preterm births.

The total parenteral nutrition type segment reached a revenue of USD 8.7 billion in 2023 and will grow significantly through 2032, due to its role in providing complete nutrition to patients who cannot consume food orally.

North America recorded 42.7% of the intravenous solutions industry share in 2023 and is expected to dominate throughout 2024 and 2032 attributed to the advanced healthcare infrastructure in the region, a strong focus on patient care, and high healthcare expenditure.

Ajinomoto Co., Inc., Amanta Healthcare, Axa Parenterals Ltd, B. Braun Melsungen AG, Baxter International Inc., Fresenius Kabi USA, LLC, Grifols, S.A., ICU Medical. Inc., JW Life Science, Otsuka Pharmaceutical Co., Ltd, and Pfizer, Inc.